I see 2024 as being a critical year for IMU. The company has...

I see 2024 as being a critical year for IMU. The company has exposed itself to enormous expenditure with the acquisition of the Azer-Cel manufacturing facility in North Carolina and its associated wages and leasing costs plus the additional wages for the number of highly qualified staff it has recently employed. There is no way the company can continue to pay these costs unless it accepts a high priced takeover offer or generates significant revenue this year. I don't think the company can survive another ill-conceived capital raise.
The directors have certainly put their heads on the chopping block which means that they must be totally convinced that they will receive FDA approval and commence manufacturing and sale very soon, or they are very close to a takeover, or they are just plain delusional. I hope it is not the latter.